Atlas Trials

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Clinical trial NCT02516241 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT02516241
Sponsor
AstraZeneca
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Urothelial Cancer
Start date
2015-11-02
Primary completion
2020-01-27
Enrollment
1126

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.